Effect of remdesivir in COVID-19

Phase 2

• Conditions: COVID-19.; Corona virus infection, unspecified; U07.1

• Registration Number: IRCT20200404046937N5
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age =18 years
Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19
Severe pulmonary involvement in imaging that progresses despite receiving standard treatment protocols within 72 hours of starting antiviral therapy
Oxygen saturation less than 90% with canola nasal or respiratory rate more than 30

Exclusion Criteria

Treatment with other antiviral drugs not listed in the national protocol
Comorbidities such as malignancy, advanced heart failure, cirrhosis, dialysis patients, stroke, Alzheimer's, advanced neurological disease, progressive respiratory disease
Allergic reaction to Remdesivir
Pregnant or lactating women
Possibility of transfer to another hospital that does not have access to study drugs
Evidence of multiple organ failure
Receive any experimental treatment for Covid 19
Patients under mechanical ventilation at the beginning of the study
Alanine Aminotransferase or Aspartate Aminotransferase more than 5 times normal
Creatinine clearance less than 50 ml per minute

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ength of stay. Timepoint: The first day and the last day of the patient's hospitalization. Method of measurement: patient file.;Oxygen Saturation. Timepoint: Daily. Method of measurement: Pulls oximeter.

Secondary Outcome Measures

Name	Time	Method
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Respiratory Rate. Timepoint: Daily. Method of measurement: Patients interview and patient file.;C-Reactive protein. Timepoint: The first day and the seventh day of study. Method of measurement: Agglutination kit.;Lymphocyte blood count. Timepoint: The first day and the seventh day of study. Method of measurement: Cell counter.;Alanine Amino Transferase. Timepoint: The first day and the seventh day of study. Method of measurement: Determination of enzyme in serum by biochemical method.;Aspartate Aminotransferase. Timepoint: The first day and the seventh day of study. Method of measurement: Determination of enzyme in serum by biochemical method.